Journal
CANCER LETTERS
Volume 557, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2023.216078
Keywords
Glioblastoma; TMZ; DSB; RBBP4; Chemoradiotherapy resistance
Categories
Ask authors/readers for more resources
In this study, it was found that RBBP4 regulates the expression of the Mre11-Rad50-NBS1(MRN) complex and DNA-DSB repair, and plays a role in glioblastoma resistance to chemotherapy and radiotherapy. Disruption of RBBP4 increased the sensitivity of GBM cells to chemotherapy and radiotherapy, and enhanced the therapeutic effects through an independent pathway of MGMT. These findings suggest that targeting the RBBP4-MRN complex regulation axis may be a promising strategy for sensitizing GBM to therapy.
For treatment of glioblastoma (GBM), temozolomide (TMZ) and radiotherapy (RT) exert antitumor effects by inducing DNA double-strand breaks (DSBs), mainly via futile DNA mismatch repair (MMR) and inducing apoptosis. Here, we provide evidence that RBBP4 modulates glioblastoma resistance to chemotherapy and radiotherapy by recruiting transcription factors and epigenetic regulators that bind to their promoters to regulate the expression of the Mre11-Rad50-NBS1(MRN) complex and the level of DNA-DSB repair, which are closely associated with recovery from TMZ-and radiotherapy-induced DNA damage in U87MG and LN229 glioblastoma cells, which have negative MGMT expression. Disruption of RBBP4 induced GBM cell DNA damage and apoptosis in response to TMZ and radiotherapy and enhanced radiotherapy and chemotherapy sensitivity by the inde-pendent pathway of MGMT. These results displayed a possible chemo-radioresistant mechanism in MGMT negative GBM. In addition, the RBBP4-MRN complex regulation axis may provide an interesting target for developing therapy-sensitizing strategies for GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available